2021年非小细胞肺癌内科治疗进展  

ADVANCES IN MEDICAL TREATMENT FOR NON-SMALL CELL LUNG CANCER IN 2021

作　　者：陈谦 刘延国[1] 刘联[1] 王秀问[1] CHEN Qian;LIU Yanguo;LIU Lian;WANG Xiuwen(Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan 250012, China)

机构地区：[1]山东大学齐鲁医院肿瘤内科,山东济南250012

出　　处：《精准医学杂志》2022年第1期85-92,共8页Journal of Precision Medicine

基　　金：国家自然科学基金面上项目(81874044)。

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)是我国发病率和死亡率最高的恶性肿瘤之一,严重威胁人民生命健康。在过去的2021年,NSCLC各分期在免疫治疗、靶向治疗等领域取得了一系列的研究进展,为NSCLC诊疗提供了新的策略和选择,并显著改善了患者的生存预后。本文就早期、局部晚期和晚期NSCLC治疗领域的重要进展进行综述,为临床治疗决策提供依据和参考。Non-small cell lung cancer(NSCLC)is one of the malignant tumors with high morbidity and mortality in China and greatly threatens the health of the Chinese people.In the past year of 2021,a series of research advances have been achieved in the treatment of NSCLC at each stage,especially in immunotherapy and targeted therapy,which provides new strategies and options for the diagnosis and treatment of NSCLC and significantly improves the survival and prognosis of patients.This article reviews the important advances in the treatment of early-stage,locally advanced,and advanced NSCLC,so as to provide a reference for clinical decisions.

关 键 词：癌 非小细胞肺 免疫疗法 分子靶向治疗 免疫检查点抑制剂 综述 

分 类 号：R734.2[医药卫生—肿瘤]